NAGE: Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw $29.8M in net sales, 23% DTC growth, and $1M net income, with strong gross margins and $66.7M in cash. Strategic launches in telehealth and pharmaceuticals, plus regulatory wins, position the company for future growth despite rising expenses and competitive pressures.Original document: Niagen Bioscience, Inc. [NAGE] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw $29.8M in net sales, 23% DTC growth, and $1M net income, with strong gross margins and $66.7M in cash. Strategic launches in telehealth and pharmaceuticals, plus regulatory wins, position the company for future growth despite rising expenses and competitive pressures.
Original document: Niagen Bioscience, Inc. [NAGE] SEC 8-K Current Report — Aug. 4 2026